Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma

Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma

Monoclonal antibodies (mAbs) directed against antigen-specific of multiple myeloma (MM) cells have Fc-dependent immune effector mechanisms, such as complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP), but the c...

Full description

Bibliographic Details
Main Authors: Alessandra Romano, Paola Storti, Valentina Marchica, Grazia Scandura, Laura Notarfranchi, Luisa Craviotto, Francesco Di Raimondo, Nicola Giuliani
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Oncology
Subjects:
monoclonal antibodies
multiple myeloma
CD38
SLAMF7
BCMA
antibody-drug conjugate
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.684561/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.684561/full

Similar Items